Navigation Links
New drug active against most aggressive type of lung cancer cells

Manchester scientists have shown that a new drug could prove useful in treating small cell lung cancer - the most aggressive form of lung cancer.

Scientists from the Cancer Research UK Manchester Institute, based at The University of Manchester and part of the Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug known as AZD3965 - on small cell lung cancer cells.

The research, published in the journal Clinical Cancer Research, also helps identify which patients are most likely to respond to the treatment.

One treatment approach currently being investigated by cancer scientists is finding drugs that exploit the change in energy production in tumours. In cancer cells there is a switch to using glycolysis, a process that requires less oxygen and produces lactate as a by-product. Certain molecules monocarboxylate transporters (MCTs) are involved in the movement of lactate out of cells and drugs that target MCTs have been shown to stop tumour growth.

The Manchester researchers tested a new drug that targets one of these molecules, MCT1, in lung cancer cells and in mouse models.

Professor Caroline Dive, who led the research, said: "Small cell lung cancer has a dismal prognosis and we have seen little improvement in treatment for many years. More targeted therapies are needed to help those patients whose tumours become resistant to chemotherapy. This new drug AZD3965 is currently in clinical trials, but it has not yet been tested in small cell lung cancer."

The team investigated the sensitivity of small cell lung cancer cells to AZD3965 and showed that in those cells lacking an alternate lactate transporter, MCT4, the drug had an effect. They found that the drug increased the level of lactate in cells and, more importantly, reduced tumour growth.

They then looked at tumour samples taken from lung cancer patients and found that high levels of MCT1 were linked to worse patient prognosis.

Professor Dive added: "We propose that this drug will be most useful in this subset of patients who have elevated MCT1 levels and need more effective treatments.

"Our laboratory results are promising and certainly provide encouragement to test this treatment clinically in patients with small cell lung cancer."

Susan Galbraith, head of the oncology innovative medicines unit at AstraZeneca, said: "Lung cancer is still the leading cancer killer, and we are working on a number of potential treatment options that could provide patients with a better chance of beating the disease. Targeting tumour cell metabolism represents a novel and exciting approach, and we are delighted to be working with The University of Manchester and Cancer Research UK to investigate the utility of AZD 3965 as a potential novel cancer treatment."


Contact: Alison Barbuti
University of Manchester

Related medicine news :

1. Most prostate cancer specialists dont recommend active surveillance for low-risk patients
2. Keeping active pays off even in your 70s and 80s
3. A new Kabuto-like nickel catalyst forms bioactive frameworks from phenol derivatives
4. Screen of existing drugs finds compounds active against MERS coronavirus
5. Faster dental treatment with new photoactive molecule
6. Resin infiltration effects in a caries-active environment -- 2 year results
7. Beaumont holds first international congress on underactive bladder
8. Beauty & bacteria: Slim, attractive men have less nasal bacteria than heavy men
9. Attractive professional cyclists are faster
10. PhUSE Working Group Active in Developing Standard Analysis Scripts
11. Rehabilitation Robots, Active Prostheses, and Exoskeletons: Market Shares, Strategies, and Forecasts, Worldwide, 2014 to 2020 New Report Available at
Post Your Comments:
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology: